SIRT for Potentially Resectable HCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SIRT for Potentially Resectable HCC — Stella

Home/Hepatocellular Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Hepatocellular Carcinoma trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong

Key details

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Enrollment target

~35 participants

Started

August 2023

Primary completion

August 2026

Age range

18 Years – 75 Years

Last updated September 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.